Seizert Capital Partners LLC Has $52.43 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Seizert Capital Partners LLC has increased its equity position in Regeneron Pharmaceuticals by 52.2%, owning a total of 82,672 shares after purchasing 28,368 shares in the first quarter.
• Regeneron Pharmaceuticals reported a quarterly EPS of $8.22, which missed analyst expectations and reflected a 3.7% decline in revenue year-over-year.
• The company's current dividend yield stands at 0.63% with an annualized dividend of $3.52, indicating a low dividend payout ratio of 8.96%.

Seizert Capital Partners LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 52.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,672 shares of the biopharmaceutical company's stock after buying an additional 28,368 shares during the period. Regeneron Pharmaceuticals accounts for approximately 2.4% of Seizert Capital Partners LLC's investment portfolio, making the stock its 11th largest position. Seizert Capital Partners LLC owned 0.08% of Regeneron Pharmaceuticals worth $52,433,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in REGN. Capital International Investors increased its stake in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. GAMMA Investing LLC increased its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Pacer Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $13.41 during mid-day trading on Friday, reaching $558.87. The company had a trading volume of 1,656,418 shares, compared to its average volume of 858,977. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The stock has a market capitalization of $60.34 billion, a P/E ratio of 14.08, a P/E/G ratio of 2.10 and a beta of 0.33. The stock's 50-day simple moving average is $538.05 and its two-hundred day simple moving average is $603.39. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Citigroup restated a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Morgan Stanley restated an "overweight" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.